Vertex Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. 

CEO
Reshma Kewalramani
CEOReshma Kewalramani
Employees
6,100
Employees6,100
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
1989
Founded1989
Employees
6,100
Employees6,100

VRTX Key Statistics

Market cap
98.92B
Market cap98.92B
Price-Earnings ratio
27.57
Price-Earnings ratio27.57
Dividend yield
Dividend yield
Average volume
1.96M
Average volume1.96M
High today
$387.48
High today$387.48
Low today
$379.72
Low today$379.72
Open price
$381.91
Open price$381.91
Volume
1.84M
Volume1.84M
52 Week high
$519.88
52 Week high$519.88
52 Week low
$362.50
52 Week low$362.50

VRTX News

TipRanks 3d
Morning Movers: CarMax slips following second quarter results

Stock futures are inching lower, reflecting a shift toward more defensive posturing ahead of key inflation data and further signals from the Fed. Equity markets...

TipRanks 3d
Vertex Pharmaceuticals granted breakthrough therapy designation for povetacicept

Vertex Pharmaceuticals (VRTX) announced that the FDA has granted breakthrough therapy designation to povetacicept for the treatment of IgAN. Pove is an investig...

TipRanks 3d
Vertex Pharmaceuticals completes enrollment in IA cohort of AMPLITUDE trial

Vertex also announced enrollment completion of the IA cohort of AMPLITUDE, a global Phase 2/3 clinical trial designed to assess the impact of inaxaplin on kidne...

Analyst ratings

62%

of 34 ratings
Buy
61.8%
Hold
35.3%
Sell
2.9%

More VRTX News

Simply Wall St 4d
Assessing Vertex Pharmaceuticals Valuation After Recent Share Price Dip

Advertisement Most Popular Narrative: 20.9% Undervalued Vertex Pharmaceuticals (VRTX) has drawn investor attention lately, though not because of a headline-gr...

Assessing Vertex Pharmaceuticals Valuation After Recent Share Price Dip
TipRanks 4d
Vertex Pharmaceuticals: Strong Market Position and Growth Potential Drive Buy Rating

Analyst Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals and keeping the price target at $565.00. Elevate Your Inv...

People also own

Based on the portfolios of people who own VRTX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.